Lexicon Could Receive Up To $610 Million In Funding From Invus, Symphony
This article was originally published in The Pink Sheet Daily
Executive Summary
Infusion of venture capital will allow Lexicon to delay commercialization partnerships until its small molecule pipeline is more mature, firm says.